Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009820 | 0.87 | NAMPT (0.42) | ALDH1A1NPC1LMNACYP3A4MEN1 | |
| SCHEMBL6521740 | 0.85 | LMNA (0.54) | FAAHDPP4ALDH1A1NPC1LMNA | |
| SCHEMBL13629808 | 0.84 | EPHX2 (0.43) | ALDH1A1NPC1LMNAMEN1TSHR | |
| SCHEMBL4957159 | 0.83 | GAA (0.38) | ALDH1A1NPC1LMNAMEN1TSHR | |
| SCHEMBL13002469 | 0.81 | DPP4 (0.44) | FAAHDPP4ALDH1A1NPC1CYP3A4 | |
| SCHEMBL22900244 | 0.81 | MEN1 (0.35) | FAAHDPP4CYP3A4MEN1KMT2A | |
| SCHEMBL10146693 | 0.81 | ALDH1A1 (0.60) | FAAHDPP4ALDH1A1NPC1LMNA | |
| SCHEMBL12384373 | 0.81 | FAAH (0.43) | FAAHDPP4ALDH1A1NPC1CYP3A4 | |
| SCHEMBL13965734 | 0.80 | HRH3 (0.55) | FAAHALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL23518518 | 0.80 | ALDH1A1 (0.42) | FAAHDPP4ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | FAAH 47/4885DPP4 557/4885ALDH1A1 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.